日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial

不可切除肝细胞癌患者接受 tremelimumab 联合 durvalumab 治疗和 durvalumab 单药治疗的免疫介导不良事件和总生存期:HIMALAYA III 期随机临床试验

Lau, George; Sangro, Bruno; Cheng, Ann-Lii; Kudo, Masatoshi; Kelley, Robin Kate; Tak, Won Young; Gasbarrini, Antonio; Reig, Maria; Lim, Ho Yeong; Tougeron, David; De Toni, Enrico N; Tam, Vincent C; Mody, Kabir; Gong, Jun; Crysler, Oxana V; Sukeepaisarnjaroen, Wattana; Lipatov, Oleg; Morimoto, Manabu; Archambeaud, Isabelle; Burgio, Valentina; Phuong, Le Thi Tuyet; Chao, Yee; Peron, Jean-Marie; Berres, Marie-Luise; Ko, Yoo-Joung; Ran, Di; Makowsky, Mallory; Negro, Alejandra; Abou-Alfa, Ghassan K

Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials

拓宽入组门槛:胰腺癌和胆道癌试验中潜在可修改的研究入组标准分析

Saj, Fen; Namayanja, Felicity K; Xiao, Lianchun; Borad, Mitesh J; Kelley, Robin Kate; Goyal, Lipika; Azad, Nilofer S; Bachini, Melinda; Lindsey, Stacie; Pant, Shubham; Valle, Juan W; Fashoyin-Aje, Lola A; Javle, Milind

Linkage disequilibrium score regression identifies genetic correlations between hepatocellular carcinoma and clinically relevant traits

连锁不平衡评分回归分析可识别肝细胞癌与临床相关性状之间的遗传关联。

Han, Younghun; Shaw, Vikram R; Byun, Jinyoung; Thrift, Aaron P; Zhu, Catherine; Li, Donghui; Hatia, Rikita I; Kelley, Robin Kate; Cleary, Sean P; Lok, Anna S; Bracci, Paige M; Permuth, Jennifer B; Bucur, Roxana; Knox, Jennifer; Yuan, Jian-Min; Singal, Amit G; Jalal, Prasun K; Ghobrial, R Mark; Kono, Yuko; Shah, Dimpy P; Nguyen, Mindie H; Parikh, Neehar D; Kim, Richard; Wu, Hui-Chen; El-Serag, Hashem; Chang, Ping; Chun, Yun Shin; Gu, Jian; Huff, Chad; Rashid, Asif; Hwang, Lu-Yu; Klein, Alison P; Khaderi, Saira A; Kaseb, Ahmed O; McGlynn, Kathrine A; Roberts, Lewis R; Hassan, Manal M; Amos, Christopher I

Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis

Durvalumab 和 Tremelimumab 作为一线治疗方案用于不可切除且预后不良的肝细胞癌患者的 3b 期 SIERRA 研究的早期安全性结果

Chan, Stephen Lam; Kudo, Masatoshi; Sangro, Bruno; Kelley, Robin Kate; Kim, Jee Hyun; Pham, Binh; Hong, Jung Yong; Waldschmidt, Dirk-Thomas; Marino, Donatella; Joycelyn Lee, Jie Xin; Gerolami, René; Burgoyne, Adam M; Li, Qiao; Nakamura, Hitomi; Sun, Peng; Baur, Boris; Rimassa, Lorenza

Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma

来自 HIMALAYA III 期研究的患者报告结局:Tremelimumab 联合 Durvalumab 治疗不可切除肝细胞癌

Sangro, Bruno; Galle, Peter R; Kelley, Robin Kate; Charoentum, Chaiyut; De Toni, Enrico N; Ostapenko, Yurii; Heo, Jeong; Cheng, Ann-Lii; Wilson Woods, Andrea; Gupta, Charu; Abraham, Jayne; McCoy, Carrie L; Patel, Nikunj; Negro, Alejandra; Vogel, Arndt; Abou-Alfa, Ghassan K

Genome-wide association study identifies high-impact susceptibility loci for HCC in North America

全基因组关联研究揭示北美肝细胞癌高影响易感基因位点

Hassan, Manal M; Li, Donghui; Han, Younghun; Byun, Jinyoung; Hatia, Rikita I; Long, Erping; Choi, Jiyeon; Kelley, Robin Kate; Cleary, Sean P; Lok, Anna S; Bracci, Paige; Permuth, Jennifer B; Bucur, Roxana; Yuan, Jian-Min; Singal, Amit G; Jalal, Prasun K; Ghobrial, R Mark; Santella, Regina M; Kono, Yuko; Shah, Dimpy P; Nguyen, Mindie H; Liu, Geoffrey; Parikh, Neehar D; Kim, Richard; Wu, Hui-Chen; El-Serag, Hashem; Chang, Ping; Li, Yanan; Chun, Yun Shin; Lee, Sunyoung S; Gu, Jian; Hawk, Ernest; Sun, Ryan; Huff, Chad; Rashid, Asif; Amin, Hesham M; Beretta, Laura; Wolff, Robert A; Antwi, Samuel O; Patt, Yehuda; Hwang, Lu-Yu; Klein, Alison P; Zhang, Karen; Schmidt, Mikayla A; White, Donna L; Goss, John A; Khaderi, Saira A; Marrero, Jorge A; Cigarroa, Francisco G; Shah, Pankil K; Kaseb, Ahmed O; Roberts, Lewis R; Amos, Christopher I

Cataracts Associated With Fibroblast Growth Factor Receptor Inhibitors for Cholangiocarcinoma

胆管癌的成纤维细胞生长因子受体抑制剂相关白内障

Kassaye, Isabell; Alyafaie, Adam; Zhang, Karen; Lifton, Jacob; Gordan, John D; Kelley, Robin Kate; Yung, Madeline

(68)Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with (18)F-FDG

(68)Ga-FAP-2286 PET在实体瘤中的应用:生物分布、剂量学及与(18)F-FDG的比较

Kline, Brad; Yadav, Surekha; Seo, Youngho; Ippisch, Robin Cumming; Castillo, Jessa; Aggarwal, Rahul R; Kelley, Robin Kate; Behr, Spencer C; Flavell, Robert R; Lawhn-Heath, Courtney; Melisko, Michelle; Rugo, Hope S; Wang, Victoria; Yom, Sue S; Ha, Patrick; Jiang, Fei; Hope, Thomas A

Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy

肿瘤生物学和免疫浸润定义了与免疫治疗后总体生存率相关的原发性肝癌亚群

Anuradha Budhu, Erica C Pehrsson, Aiwu He, Lipika Goyal, Robin Kate Kelley, Hien Dang, Changqing Xie, Cecilia Monge, Mayank Tandon, Lichun Ma, Mahler Revsine, Laura Kuhlman, Karen Zhang, Islam Baiev, Ryan Lamm, Keyur Patel, David E Kleiner, Stephen M Hewitt, Bao Tran, Jyoti Shetty, Xiaolin Wu, Yongm

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

不可切除肝细胞癌患者接受曲美利单抗单药治疗或联合度伐利尤单抗治疗的暴露-反应分析

Song, Xuyang; Kelley, Robin Kate; Khan, Anis A; Standifer, Nathan; Zhou, Diansong; Lim, KyoungSoo; Krishna, Rajesh; Liu, Lu; Wang, Kun; McCoon, Patricia; Negro, Alejandra; He, Philip; Gibbs, Megan; Kurland, John F; Abou-Alfa, Ghassan K